A clear trend of slower CL for S104 was noted with the increased severity of HI.
← all excerpts
Pharmacokinetics, safety, and tolerability of BMS-986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment.
1
—
—
A clear trend of slower CL for S104 was noted with the increased severity of HI.